# BioNexus

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bionexus

- Industry: Healthcare IT
- Headquarters: Suwon, South Korea
- Website: https://bionexus.kr/
- Latest round: Seed (Aug 7, 2026)
- Investors on record: 2

## About

Based in Suwon, South Korea, and founded in 2024, BioNexus develops AI and bioinformatics solutions for research, diagnostics, and healthcare applications. The company operates its headquarters in Suwon and maintains research facilities in both Suwon and Seoul. According to the company website, BioNexus has expanded through collaborations with universities, government agencies, hospitals, and research institutes, while securing multiple AI and bioinformatics-related projects. The company also established a corporate research institute in 2025 and completed capital increases through new share issuances in 2025. In August 2026,  BioNexus raised an undisclosed amount of seed funding from new investors Base Ventures and SMB Investment Partners. The company focuses on AI-powered bio data analysis and research automation solutions. Its key offerings include Co-Scientist, an AI research assistant platform, and Agentic-RAG, a knowledge retrieval and analysis solution. BioNexus leverages AI, large language models (LLMs), genomics data, and biological big data to support hypothesis generation, research design, biomarker discovery, drug development, and scientific data analysis. The company's revenue is generated by providing AI bioinformatics platforms, research automation solutions, data analysis services, technology development projects, and contract research engagements for government agencies, research institutes, universities, hospitals, and corporate clients. The company website also references multiple awarded projects, research service contracts, and collaborative programs as part of its business activities. Based on the company's most recent activities, BioNexus appears focused on expanding its AI-powered life science research platform, strengthening collaborations with healthcare and biotechnology organizations, and advancing technologies involving multi-agent AI systems, large language models, biomarker discovery, and precision healthcare. The company's stated mission is to reduce the time and cost of life science research through AI and bio data while building a data-driven healthcare platform for healthier and longer lives.

## Funding rounds

- Seed, Aug 7, 2026 — Base Ventures, SMB Investment Partners

## Investors

- Base Ventures (https://capitalatlas.ai/funds/base-ventures) — Seed
- SMB Investment Partners (https://capitalatlas.ai/funds/smb-investment-partners) — Seed